Latest news newssearch boxGO 11 Jul 2018 Idorsia successfully completes the offering of new shares and the offering of convertible bonds thereby securing long-term funding for the development of its advancing pipeline 10 Jul 2018 Idorsia launches the offering of new shares in combination with the offering of convertible bonds to fund the development of its advancing pipeline 20 Jun 2018 Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management 18 Jun 2018 Idorsia is initiating REACT - Phase 3 registration study with clazosentan 11 Jun 2018 Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia 16 May 2018 Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease 24 Apr 2018 Idorsia holds its first Annual General Meeting of Shareholders - All Board proposals approved 19 Apr 2018 Idorsia announces financial results for the first quarter 2018 19 Mar 2018 Idorsia issues invitation to 2018 Annual General Meeting of Shareholders 06 Feb 2018 Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development 20 Dec 2017 Idorsia forms research collaboration with Roche in the field of cancer immunotherapy 04 Dec 2017 Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577) 24 Oct 2017 Idorsia announces financial results as of 30 September 2017 03 Aug 2017 Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company 28 Jul 2017 ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia 16 Jun 2017 Idorsia - Reaching out for more 1 2
